SCHEMBL20239293

SCHEMBL20239293

CC(=O)NCCc1ccc(Oc2cc(C#N)nc(Cl)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.52
ACACB O00763 9/20 0.47
PLAAT3 P53816 1/20 0.45
PLAAT5 Q96KN8 1/20 0.45
PLAAT2 Q9NWW9 1/20 0.45
PLAAT4 Q9UL19 1/20 0.45
MTNR1A P48039 1/20 0.44
MTNR1B P49286 1/20 0.44
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
PTGS1 P23219 1/20 0.43
BLM P54132 1/20 0.43
HIF1A Q16665 1/20 0.43
HSD17B10 Q99714 1/20 0.43
F13A1 P00488 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239253 0.82 ALDH1A1 (0.43) SMN1; SMN2PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL20239352 0.82 SMN1; SMN2 (0.56) SMN1; SMN2ACACBMTNR1AMTNR1BALDH1A1
SCHEMBL20239351 0.80 SMN1; SMN2 (0.53) SMN1; SMN2ACACBMTNR1AMTNR1BMAPT
SCHEMBL20239138 0.80 EPHX2 (0.43) SMN1; SMN2ACACBPLAAT3PLAAT5PLAAT2
SCHEMBL20239189 0.76 RAB9A (0.46) SMN1; SMN2ACACBPLAAT3PLAAT5PLAAT2
SCHEMBL20259130 0.74 GLA (0.42) SMN1; SMN2MAPT
SCHEMBL20259076 0.74 RAB9A (0.47) SMN1; SMN2ALDH1A1MAPT
SCHEMBL20239326 0.73 ALDH1A1 (0.43) SMN1; SMN2ACACBPLAAT3PLAAT5PLAAT2
SCHEMBL3727682 0.73 MTNR1A (0.55) ACACBMTNR1AMTNR1B
SCHEMBL18249758 0.73 DGAT2 (0.41) SMN1; SMN2KDM4EALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT SMN1; SMN2 4828/4885ACACB 152/4885PLAAT3 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.